Polaris Partners, formerly Polaris Venture Partners, focuses on early-stage investments in disruptive opportunities across the healthcare, life sciences, and technology sectors. The firm also operates specialized funds, including the Polaris Growth Fund for profitable, founder-owned technology companies and the Polaris Innovation Fund for early-stage academic research with commercial potential.
36% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (6 deals in the last 12 months). Average disclosed round size is $72.2M (across 64 rounds with reported amounts).
Portfolio
67
Fund Size
$5B
Top Stage
Series C
Last 12 Mo
6
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
67 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Tropic | Series C | $105M | Mar 2026 |
 Kash | Pre-Seed | $2M | Feb 2026 |
| TTRexBio | Series C | $50M | Jan 2026 |
 EpiBiologics | Series B | $107M | Jan 2026 |
 Zag Bio | Series A | $80M | Oct 2025 |
 Cirrus Therapeutics | Seed | $11M | Oct 2025 |
 Noema Pharma | Series B | — | Dec 2024 |
 ByHeart | Growth | $95M | May 2024 |
 JIBE Inc. | Seed | $875K | Mar 2024 |
 Cohere Health | Series C | $50M | Feb 2024 |
 Vico Therapeutics B.V. | Series B | $60M | Jan 2024 |
 Tome Biosciences | Series B | $213M | Dec 2023 |
 Triveni Bio Inc. | Series A | $92M | Oct 2023 |
 65LAB | Unknown | — | Oct 2023 |
| SSimon Data | Series D | $54M | Aug 2023 |
 Candesant Biomedical | Series B | $35M | Jun 2023 |
| PParatus Sciences | Series D | $100M | Feb 2023 |
 Jnana Therapeutics | Series C | $107M | Nov 2022 |
 FOLX Health | Series B | $30M | Oct 2022 |
 Auron Therapeutics | Series A | $48M | Jul 2022 |
 Podimetrics | Series C | $45M | Mar 2022 |
 Dewpoint Therapeutics | Series C | $150M | Feb 2022 |
 Freenome | Series D | $300M | Dec 2021 |
 Muna Therapeutics | Series A | $73M | Jul 2021 |
| ByHeart | Series B | $90M | Jul 2021 |
Page 1 of 3
Top Co-Investors
GV (Google Ventures)8 shared
ARCH Venture Partners6 shared
Invus6 shared
D1 Capital Partners5 shared
F-Prime Capital5 shared
Alexandria Venture Investments5 shared
.406 Ventures4 shared
RA Capital Management4 shared
Kaiser Permanente Ventures4 shared
Section 324 shared
Flare Capital Partners4 shared
Khosla Ventures4 shared
Perceptive Advisors3 shared
Bain Capital Life Sciences3 shared
Cormorant Asset Management3 shared
Janus Henderson Investors3 shared
Bessemer Venture Partners3 shared
Eli Lilly and Company3 shared
Temasek Holdings3 shared
General Catalyst3 shared
Last updated: 24 April 2026